Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

DOI PDF PubMed 被引用文献16件 参考文献51件 オープンアクセス
  • Junko Murai
    Authors' Affiliations: 1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
  • Shar-Yin N. Huang
    Authors' Affiliations: 1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
  • Amèlie Renaud
    Authors' Affiliations: 1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
  • Yiping Zhang
    Authors' Affiliations: 1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
  • Jiuping Ji
    Authors' Affiliations: 1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
  • Shunichi Takeda
    Authors' Affiliations: 1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
  • Joel Morris
    Authors' Affiliations: 1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
  • Beverly Teicher
    Authors' Affiliations: 1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
  • James H. Doroshow
    Authors' Affiliations: 1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan
  • Yves Pommier
    Authors' Affiliations: 1Developmental Therapeutics Branch, Laboratory of Molecular Pharmacology, Center for Cancer Research; 2National Clinical Target Validation Laboratory; 3Division of Cancer Treatment and Diagnosis, National Cancer Institute, NIH, Bethesda, Maryland; and 4Department of Radiation Genetics, Graduate School of Medicine, Kyoto University, Yoshidakonoe, Sakyo-ku, Kyoto, Japan

説明

<jats:title>Abstract</jats:title> <jats:p>Anti-PARP drugs were initially developed as catalytic inhibitors to block the repair of DNA single-strand breaks. We recently reported that several PARP inhibitors have an additional cytotoxic mechanism by trapping PARP–DNA complexes, and that both olaparib and niraparib act as PARP poisons at pharmacologic concentrations. Therefore, we have proposed that PARP inhibitors should be evaluated based both on catalytic PARP inhibition and PARP–DNA trapping. Here, we evaluated the novel PARP inhibitor, BMN 673, and compared its effects on PARP1 and PARP2 with two other clinical PARP inhibitors, olaparib and rucaparib, using biochemical and cellular assays in genetically modified chicken DT40 and human cancer cell lines. Although BMN 673, olaparib, and rucaparib are comparable at inhibiting PARP catalytic activity, BMN 673 is ∼100-fold more potent at trapping PARP–DNA complexes and more cytotoxic as single agent than olaparib, whereas olaparib and rucaparib show similar potencies in trapping PARP–DNA complexes. The high level of resistance of PARP1/2 knockout cells to BMN 673 demonstrates the selectivity of BMN 673 for PARP1/2. Moreover, we show that BMN 673 acts by stereospecific binding to PARP1 as its enantiomer, LT674, is several orders of magnitude less efficient. BMN 673 is also approximately 100-fold more cytotoxic than olaparib and rucaparib in combination with the DNA alkylating agents methyl methane sulfonate (MMS) and temozolomide. Our study demonstrates that BMN 673 is the most potent clinical PARP inhibitor tested to date with the highest efficiency at trapping PARP–DNA complexes. Mol Cancer Ther; 13(2); 433–43. ©2013 AACR.</jats:p>

収録刊行物

被引用文献 (16)*注記

もっと見る

参考文献 (51)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ